score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS01448-6115224	PROS01448-6115224-Tumor-SM-67ERT	
Investigate Actionability - High	Preclinical		Clinical evidence	Rearrangement	TMPRSS2	Fusion	TMPRSS2--ETV4			0.0	0.0		Investigate Actionability - High	Rucaparib	Targeted therapy	Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.	Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.	https://doi.org/10.1371/journal.pone.0060408							Investigate Actionability - High	0.0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.	https://doi.org/10.1038/sj.onc.1210237	0				TMPRSS2--ETV4 Fusion	0.0	PROS01448-6115224		
Investigate Actionability - High	Inferential			Mutational Signature	COSMIC Signature 5		0.233						Investigate Actionability - High	Cisplatin	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557												0				COSMIC Signature 5 (23%)		PROS01448-6115224		
Investigate Actionability - Low	Guideline			Somatic Variant	TET2	Missense	p.A277T	0.0412	97.0	2.5e-05	0.0		Investigate Actionability - Low	Azacitidine	Targeted therapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf												0	1.0	0.0	0.0	TET2 p.A277T (Missense)		PROS01448-6115224	PROS01448-6115224-Tumor-SM-67ERT	PROS01448-6115224-Normal-SM-67EST
Investigate Actionability - Low			Clinical evidence	Somatic Variant	PRPF8	Nonsense	p.W1827*	0.3427	143.0	0.0	0.0														Investigate Actionability - Low	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	36.0	0.0833	0.9991	PRPF8 p.W1827* (Nonsense)		PROS01448-6115224	PROS01448-6115224-Tumor-SM-67ERT	PROS01448-6115224-Normal-SM-67EST
Investigate Actionability - Low			Clinical evidence	Somatic Variant	PRPF8	Nonsense	p.W1827*	0.3517	145.0	0.0	0.0														Investigate Actionability - Low	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	36.0	0.0833	0.9994	PRPF8 p.W1827* (Nonsense)		PROS01448-6115224	PROS01448-6115224-Tumor-SM-67ERT	PROS01448-6115224-Normal-SM-67EST
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P579L	0.2025	242.0	0.0	0.0																			0	1.0	0.0	0.0	ROS1 p.P579L (Missense)		PROS01448-6115224	PROS01448-6115224-Tumor-SM-67ERT	PROS01448-6115224-Normal-SM-67EST
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		PROS01448-6115224		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.324																							0				COSMIC Signature 1 (32%)		PROS01448-6115224		
